Granting Stock Options to Directors and Employees
First written in FY2017-Q1. 7 of 17 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2027-H1.
- FY2027-H1No new stock options applicableAnnual report
「① Details of the stock option plan There are no applicable matters. ② Status of other stock acquisition rights, etc. There are no applicable matters.」
The Company stated that there were no applicable matters concerning stock option plans or other share acquisition rights during the interim consolidated accounting period. - FY2024Decrease in the number of stock acquisition rights outstandingAnnual report
「Number of stock acquisition rights (units)* 3,600 (Note 1) Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 360,000 (Note 1) Exercise period for the stock acquisition rights 28 November 2022 to 27 November 2024」
The stock acquisition rights resolved on 11 November 2020 decreased from 3,700 units disclosed in the previous fiscal year to 3,600 units, while the number of underlying shares decreased from 370,000 to 360,000. - FY2024-Q2No new stock options applicableAnnual report
「① [Details of the stock option plan] No applicable matters.」
The company stated that there were no applicable matters concerning the stock option plan during the cumulative second quarter period. - FY2023Decrease in the number of stock acquisition rights outstandingAnnual report
「Number of stock acquisition rights (units)* 4,015 (Note 1) 3,700 (Note 1)」
The company disclosed year-end balances of 4,015 units and 3,700 units for the stock acquisition rights resolved on 12 November 2019 and 11 November 2020, respectively. The balances changed from those disclosed in the previous fiscal year due to exercises, lapses and other factors. - FY2022Decrease in the balances of Series 8 through Series 10 stock acquisition rightsAnnual report
「Number of stock acquisition rights (units)* 4,110 (Note 1) 5,375 (Note 1) 3,950 (Note 1)」
The year-end balances of the Series 8, Series 9 and Series 10 stock acquisition rights were 4,110 units, 5,375 units and 3,950 units, respectively, with the balances changing as a result of exercises and lapses. - FY2021Decrease in the balance of Series 10 stock acquisition rightsAnnual report
「Date of resolution 11 November 2020 Eligible recipients and number of recipients 2 directors of the company 73 employees of the company Number of stock acquisition rights (units)* 4,250 (Note 1) Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 425,000 (Note 1)」
The Series 10 stock acquisition rights decreased from 4,300 units and 430,000 shares stated in the previous quarterly report to 4,250 units and 425,000 shares. - FY2021-Q3AdvancedAnnual report
「Date of resolution 11 November 2020 Eligible recipients and number of recipients (people) 2 directors of the company 76 employees of the company Number of stock acquisition rights (units)* 4,300 (Note 1) Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 430,000 (Note 1) Exercise period for the stock acquisition rights* 28 November 2022 to 27 November 2024」
The company issued 4,300 Series 10 stock acquisition rights to 2 directors and 76 employees, representing 430,000 underlying shares, with an exercise period from 28 November 2022 to 27 November 2024. - FY2020AdvancedAnnual report
「The decrease in the Series 6 stock acquisition rights was due to the exercise of rights for 20,000 shares and the lapse of rights for 7,500 shares following employee departures. The decrease in the Series 7 stock acquisition rights was due to the lapse of rights for 7,500 shares following employee departures. The decrease in the Series 8 stock acquisition rights was due to the lapse of rights for 30,000 shares following employee departures. The decrease in the Series 9 stock acquisition rights was due to the lapse of rights for 22,500 shares following employee departures.」
The balance of the stock options changed, including 20,000 shares being exercised under the existing Series 6 stock acquisition rights and 22,500 shares lapsing under the Series 9 stock acquisition rights after 612,500 shares had been granted. - FY2020-Q3AdvancedAnnual report
「Date of resolution 12 November 2019 Eligible recipients and number of recipients (people) 2 directors of the company 73 employees of the company Number of stock acquisition rights (units)* 6,125 (Note 1) Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 612,500 (Note 1) Exercise period for the stock acquisition rights* 29 November 2021 to 28 November 2023」
The company issued 6,125 Series 9 stock acquisition rights to 2 directors and 73 employees, representing 612,500 underlying shares, with an exercise period from 29 November 2021 to 28 November 2023. - FY2019AdvancedAnnual report
「Vested (shares) － 410,000 － － Unvested balance (shares) － － 440,000 530,000」
410,000 shares underlying the Series 6 stock acquisition rights vested. The 440,000 shares underlying the Series 7 stock acquisition rights and 530,000 shares underlying the Series 8 stock acquisition rights remain unvested. - FY2019-Q3AdvancedAnnual report
「The stock acquisition rights issued during the third quarter accounting period were as follows: Resolution date: 9 November 2018; number of stock acquisition rights: 5,300 (Note 1); number of underlying shares: 530,000 (Note 1); exercise period: 27 November 2020 to 26 November 2022.」
The company issued 5,300 stock acquisition rights as the Series 8 stock acquisition rights, representing 530,000 underlying shares, with an exercise period from 27 November 2020 to 26 November 2022. - FY2019-Q1Decrease in the number of seventh-series stock acquisition rights outstandingAnnual report
「Seventh series of stock acquisition rights (number of stock acquisition rights: 4,550) (number of underlying shares: 455,000)」
The seventh series of stock acquisition rights decreased from 462,500 shares outstanding subject to finalization at the end of the previous fiscal year to 455,000 shares. - FY2018Forfeiture of stock acquisition rights reflectedAnnual report
「The decrease in the seventh series of stock acquisition rights was due to the forfeiture of 7,500 shares following employees' departures.」
Of the 470,000 shares granted under the seventh series of stock acquisition rights, 7,500 shares were forfeited, leaving 462,500 shares outstanding subject to finalization at year-end. Under the fifth series of stock acquisition rights, 16,000 shares were exercised. - FY2018-Q3AdvancedAnnual report
「The stock acquisition rights issued during the third quarter accounting period were as follows: Resolution date: 10 November 2017; number of stock acquisition rights: 4,700; number of underlying shares: 470,000; exercise period: 28 November 2019 to 27 November 2021.」
The company issued 4,700 stock acquisition rights representing 470,000 underlying shares as the seventh series, with an exercise period from 28 November 2019 to 27 November 2021. - FY2017RestatedAnnual report
「The stock options granted during the consolidated fiscal year are covered, and the number of stock options is stated on a share-equivalent basis.」
The company disclosed the year-end status of the sixth series of stock acquisition rights, including 440,000 shares granted, 7,500 shares forfeited and 432,500 shares outstanding subject to finalization. - FY2017-Q2AdvancedAnnual report
「The stock acquisition rights issued during the second quarter accounting period are as follows.」
The company disclosed the issue terms for stock acquisition rights granted to directors, employees and others: 4,400 rights, 440,000 underlying shares and an exercise period from 21 July 2018 to 20 July 2020. - FY2017-Q1First statedAnnual report
「At a meeting of the Board of Directors held on 5 July 2016, the company resolved, pursuant to Articles 236, 238 and 240 of the Companies Act, to issue stock acquisition rights for the purpose of granting stock options to its directors and employees. The issue comprises 4,400 stock acquisition rights, with each stock acquisition right representing 100 common shares; the number of shares underlying the stock acquisition rights is 440,000 common shares; the exercise period is from 21 July 2018 to 20 July 2020; and the eligible allottees are 2 directors and 50 employees.」
The company resolved to issue 4,400 stock acquisition rights representing 440,000 shares to directors and employees, with an exercise period from 2018 through 2020.